407 related articles for article (PubMed ID: 16605301)
21. Natural resistance to meglumine antimoniate is associated with treatment failure in cutaneous leishmaniasis caused by Leishmania (Viannia) panamensis.
Fernández OL; Rosales-Chilama M; Sánchez-Hidalgo A; Gómez P; Rebellón-Sánchez DE; Regli IB; Díaz-Varela M; Tacchini-Cottier F; Saravia NG
PLoS Negl Trop Dis; 2024 May; 18(5):e0012156. PubMed ID: 38709850
[TBL] [Abstract][Full Text] [Related]
22. A single-group trial of end-stage patients with anthroponotic cutaneous leishmaniasis: Levamisole in combination with Glucantime in field and laboratory models.
Bamorovat M; Sharifi I; Fekri A; Keyhani A; Aflatoonian MR; Heshmatkhah A; Oliaee RT; Khosravi A; Naderi A; Parizi MH; Mostafavi M; Varma RS
Microb Pathog; 2019 Mar; 128():162-170. PubMed ID: 30583021
[TBL] [Abstract][Full Text] [Related]
23. Overexpression of ubiquitin and amino acid permease genes in association with antimony resistance in Leishmania tropica field isolates.
Kazemi-Rad E; Mohebali M; Khadem-Erfan MB; Hajjaran H; Hadighi R; Khamesipour A; Rezaie S; Saffari M; Raoofian R; Heidari M
Korean J Parasitol; 2013 Aug; 51(4):413-9. PubMed ID: 24039283
[TBL] [Abstract][Full Text] [Related]
24. Glucantime efficacy in the treatment of zoonotic cutaneous leishmaniasis.
Pourmohammadi B; Motazedian MH; Handjani F; Hatam GH; Habibi S; Sarkari B
Southeast Asian J Trop Med Public Health; 2011 May; 42(3):502-8. PubMed ID: 21706927
[TBL] [Abstract][Full Text] [Related]
25. Identification of antimony resistance markers in Leishmania tropica field isolates through a cDNA-AFLP approach.
Kazemi-Rad E; Mohebali M; Khadem-Erfan MB; Saffari M; Raoofian R; Hajjaran H; Hadighi R; Khamesipour A; Rezaie S; Abedkhojasteh H; Heidari M
Exp Parasitol; 2013 Oct; 135(2):344-9. PubMed ID: 23928349
[TBL] [Abstract][Full Text] [Related]
26. Sensitivity to Glucantime of Leishmania viannia isolated from patients prior to treatment.
Robledo SM; Valencia AZ; Saravia NG
J Parasitol; 1999 Apr; 85(2):360-6. PubMed ID: 10219320
[TBL] [Abstract][Full Text] [Related]
27. Insights into the trypanothione system in antimony-resistant and sensitive Leishmania tropica clinical isolates.
Valashani HT; Ahmadpour M; Naddaf SR; Mohebali M; Hajjaran H; Latifi A; Salimi M; Farahmand M; Naeimi S; Raissi V; Kazemirad E
Acta Trop; 2024 Jun; 254():107190. PubMed ID: 38508372
[TBL] [Abstract][Full Text] [Related]
28. Heterogeneity of molecular resistance patterns in antimony-resistant field isolates of Leishmania species from the western Mediterranean area.
Jeddi F; Mary C; Aoun K; Harrat Z; Bouratbine A; Faraut F; Benikhlef R; Pomares C; Pratlong F; Marty P; Piarroux R
Antimicrob Agents Chemother; 2014 Aug; 58(8):4866-74. PubMed ID: 24913173
[TBL] [Abstract][Full Text] [Related]
29. Associated-risk determinants for anthroponotic cutaneous leishmaniasis treated with meglumine antimoniate: A cohort study in Iran.
Aflatoonian MR; Sharifi I; Aflatoonian B; Bamorovat M; Heshmatkhah A; Babaei Z; Ghasemi Nejad Almani P; Mohammadi MA; Salarkia E; Aghaei Afshar A; Sharifi H; Sharifi F; Khosravi A; Khatami M; Arefinia N; Fekri A; Farajzadeh S; Khamesipour A; Mohebali M; Gouya MM; Shirzadi MR; Varma RS
PLoS Negl Trop Dis; 2019 Jun; 13(6):e0007423. PubMed ID: 31188834
[TBL] [Abstract][Full Text] [Related]
30. Decreased sensitivity to meglumine antimoniate (Glucantime) of Leishmania infantum isolated from dogs after several courses of drug treatment.
Gramiccia M; Gradoni L; Orsini S
Ann Trop Med Parasitol; 1992 Dec; 86(6):613-20. PubMed ID: 1304703
[TBL] [Abstract][Full Text] [Related]
31. Successful treatment of lupoid cutaneous leishmaniasis with glucantime and topical trichloroacetic acid (a case report).
Nilforoushzadeh MA; Sadeghian G; Jaffary F; Ziaei H; Shirani-Bidabad L; Mahzoni P
Korean J Parasitol; 2008 Sep; 46(3):175-7. PubMed ID: 18830058
[TBL] [Abstract][Full Text] [Related]
32. Comparison of Three Different Therapies for Cutaneous Leishmaniasis and Identification of the Etiologic Isolates in Isfahan, Iran.
Abdellahi L; Hejazi SH; Amirmozafari N; Sotoodehnejadnematalahi F
Arch Iran Med; 2020 Nov; 23(11):740-748. PubMed ID: 33220690
[TBL] [Abstract][Full Text] [Related]
33. Isolation of Leishmania tropica from a patient with visceral leishmaniasis and disseminated cutaneous leishmaniasis, southern Iran.
Alborzi A; Pouladfar GR; Fakhar M; Motazedian MH; Hatam GR; Kadivar MR
Am J Trop Med Hyg; 2008 Sep; 79(3):435-7. PubMed ID: 18784238
[TBL] [Abstract][Full Text] [Related]
34. Antileishmanial effect of rapamycin as an alternative approach to control Leishmania tropica infection.
Khadir F; Taheri T; Habibzadeh S; Zahedifard F; Gholami E; Heidari-Kharaji M; Oryan A; Rafati S
Vet Parasitol; 2019 Dec; 276():108976. PubMed ID: 31739256
[TBL] [Abstract][Full Text] [Related]
35. Host's immune response in unresponsive and responsive patients with anthroponotic cutaneous leishmaniasis treated by meglumine antimoniate: A case-control study of Th1 and Th2 pathways.
Bamorovat M; Sharifi I; Aflatoonian MR; Sadeghi B; Shafiian A; Oliaee RT; Keyhani A; Afshar AA; Khosravi A; Mostafavi M; Parizi MH; Khatami M; Arefinia N
Int Immunopharmacol; 2019 Apr; 69():321-327. PubMed ID: 30771740
[TBL] [Abstract][Full Text] [Related]
36. In vitro sensitivity of Leishmania (Viannia) braziliensis and Leishmania (Leishmania) amazonensis Brazilian isolates to meglumine antimoniate and amphotericin B.
Zauli-Nascimento RC; Miguel DC; Yokoyama-Yasunaka JK; Pereira LI; Pelli de Oliveira MA; Ribeiro-Dias F; Dorta ML; Uliana SR
Trop Med Int Health; 2010 Jan; 15(1):68-76. PubMed ID: 19874570
[TBL] [Abstract][Full Text] [Related]
37. Novel approach to in vitro drug susceptibility assessment of clinical strains of Leishmania spp.
Fernández O; Diaz-Toro Y; Valderrama L; Ovalle C; Valderrama M; Castillo H; Perez M; Saravia NG
J Clin Microbiol; 2012 Jul; 50(7):2207-11. PubMed ID: 22518860
[TBL] [Abstract][Full Text] [Related]
38. Successful treatment by adding thalidomide to meglumine antimoniate in a case of refractory anthroponotic mucocutaneous leishmaniasis.
Goyonlo VM; Vahabi-Amlashi S; Taghavi F
Int J Parasitol Drugs Drug Resist; 2019 Dec; 11():177-179. PubMed ID: 31492621
[TBL] [Abstract][Full Text] [Related]
39. In vitro susceptibility to pentavalent antimony in Leishmania infantum strains is not modified during in vitro or in vivo passages but is modified after host treatment with meglumine antimoniate.
Carrió J; Portús M
BMC Pharmacol; 2002 May; 2():11. PubMed ID: 12019027
[TBL] [Abstract][Full Text] [Related]
40. Comparative mitochondrial proteomics of Leishmania tropica clinical isolates resistant and sensitive to meglumine antimoniate.
Tasbihi M; Shekari F; Hajjaran H; Khanmohammadi M; Hadighi R
Parasitol Res; 2020 Jun; 119(6):1857-1871. PubMed ID: 32350589
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
